Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

Author(s): Vicente Estrada, The TORAL Study Group, Manuel Castano, Jorge Carmena, Antonio Antela, Josefa Galindo, Esteban Ribera, Joaquin Portilla, Ferran Segura, Eugenia Negredo, Daniel Podzamczer, Hernando Knobel, Ignacio Santos, Antonio Ocampo, Maria-Jesus Perez-Elias, Jordi Curto, Pompeyo Viciana, Elena Ferrer, Pere Domingo and Esteban Martinez

Volume 10 , Issue 8 , 2012

Page: [673 - 678] Pages: 6

DOI: 10.2174/157016212803901428

Price: $65

Abstract

Objectives: To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice.

Methods: A total number of 263 subjects (189 men, median age 48.1 years) with HIV-1 RNA < 50 copies/mL for ≥ 6 months were switched to RAL (400 mg b.i.d). Reasons for change were toxicity (49.0%), drug interactions (6.1%) or convenience (28.6%) (switch from subcutaneous to oral treatment 22.4%, improvement of posology 3.4%). Patients were followed up to 24 months after switching to RAL. Primary end-points were tolerability and virological failure defined as two consecutive measures of HIV-1 RNA > 50 copies/mL.

Results: After a median of 12.4 months (range 2.8-26.4 months), virological failure was observed in 6 (2.3%) patients (2.2 per 100 person-years [95%CI 0.9-4.6]), while AIDS occurred in 1, drug discontinuation in 4, 3 patients died and 10 were lost to follow-up. The median CD4+ T cell count increased from 460 cells/mm3 to 508.6 cells/mm3 (P < 0.001).

Conclusions: Switching to RAL in clinical practice was mainly driven by toxicity, convenience or interactions, they were well tolerated and secured virologic suppression in the vast majority of patients.

Keywords: Raltegravir, simplification strategy, HIV infection, toxicity, CD4+, T cell, patients, lipid, virological, suppression


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy